NCT05714553 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05714553
Title	NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Recruitment	Terminated
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	NuCana plc
Indications	triple-receptor negative breast cancer colorectal cancer stomach cancer melanoma esophageal carcinoma malignant pleural mesothelioma head and neck squamous cell carcinoma transitional cell carcinoma skin squamous cell carcinoma endometrial carcinoma Hodgkin's lymphoma lung non-small cell carcinoma renal cell carcinoma Advanced Solid Tumor
Therapies	Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	GBR

Facility	City	Zip	Country	Details
Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust	Birmingham	B15 2TH	United Kingdom	Details
The Beatson West of Scotland Cancer Centre	Glasgow	G12 0TN	United Kingdom	Details
Guy's and St Thomas NHS Foundation Trust	London	SE1 9RT	United Kingdom	Details
The Christie NHS Foundation Trust	Manchester	M20 4BX	United Kingdom	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT05714553Clinical Trial Detail